R.E.N.A.L.复杂性评分对原发性肾细胞癌立体定向消融放疗结局的影响
单中心回顾性分析2012-2020年90例接受SABR的原发性RCC患者,中位RNS为9分,1年eGFR下降-8.1 mL/min/1.73 m2,基线RNS与eGFR轨迹无显著关联(P=0.06),局部控制良好,毒性可接受。
要点
- SABR对复杂原发性肾肿瘤患者肾功能下降和毒性可接受。
- 基线RNS与SABR后eGFR轨迹的关联P=0.06,需进一步研究。
- 3年和5年无局部失败率分别为97%和91%。
核心结论
- SABR是医学上无法手术的复杂原发性肾肿瘤患者的有效治疗选择,肾功能下降和毒性可接受。
- 基线RNS与肾功能轨迹的关联值得进一步研究。
研究设计与样本
- 单机构回顾性分析2012-2020年接受SABR的原发性RCC患者90例。
- 中位年龄77岁(IQR 71-82),中位随访4.8年(IQR 2.8-7.8)。
主要发现
- 52例(58%)为T1b期,9例(10%)为T2期,3例(3%)为T3期。
- 中位最大肿瘤大小4.6 cm(IQR 2.1-8.4),中位RNS 9分(IQR 7-10)。
- 基线中位eGFR 53.6 mL/min/1.73 m2(95%CI 49.7-57.5),1年下降-8.1 mL/min/1.73 m2(95%CI -6.5至-9.6)。
- 2例(2.2%)透析,3例(3.3%)局部进展,4例(4.4%)发生3级毒性。
- 3年和5年无局部失败率分别为97%(95%CI 89-99%)和91%(95%CI 68-98%)。
关键数值与推荐
- 基线RNS与SABR后eGFR轨迹的P=0.06。
临床怎么用
- 对于医学上无法手术的复杂原发性肾肿瘤患者,SABR可作为一种有效治疗选择。
- 需关注SABR后肾功能下降,基线RNS对肾功能轨迹的预测价值尚需进一步研究。
局限性
- 单中心回顾性分析,样本量有限。
- 基线RNS与eGFR轨迹的关联未达统计学显著性(P=0.06)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the predictive value of the R.E.N.A.L. ([R]adius, [E]xophytic/endophytic properties, [N]earness of tumour to the collecting system or sinus, [A]nterior/posterior descriptor, and [L]ocation relative to polar lines) nephrometry score (RNS) for outcomes following stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma (RCC), as the impact of tumour complexity on outcomes following nephron-sparing SABR treatment is unclear. PATIENTS AND METHODS: This was a single institutional retrospective analysis of patients with primary RCC receiving SABR between 2012 and 2020. The primary outcome was the change in renal function post-SABR, measured by estimated glomerular filtration rate (eGFR), and the effect of baseline RNS on it was assessed using linear mixed models (LMMs). RESULTS: A total of 90 patients with a median (interquartile range [IQR]) age of 77 (71-82) years and a median (IQR) follow-up of 4.8 (2.8-7.8) years were included. In all, 52 patients (58%) had T1b disease, nine (10%) had T2 disease, and three (3%) had T3 disease. The median (IQR) maximum tumour size was 4.6 (2.1-8.4) cm. Most patients had moderate-complex renal tumours with a median (IQR) RNS of 9 (7-10). The baseline median eGFR was 53.6 mL/min/1.73 m2 (95% confidence interval [CI] 49.7-57.5 mL/min/1.73 m2). The eGFR declined by -8.1 mL/min/1.73 m2 (95% CI -6.5 to -9.6 mL/min/1.73 m2) at 1 year. The P value for the post-SABR eGFR trajectory according to baseline RNS was P = 0.06. Two patients (2.2%) underwent dialysis. Three patients (3.3%) experienced local progression. The 3- and 5-year estimates for freedom from local failure were 97% (95% CI 89-99%), and 91% (95% CI 68-98%), respectively. Four (4.4%) patients experienced Grade 3 toxicities. CONCLUSION: Stereotactic ablative body radiotherapy is an effective treatment option, with acceptable decline in renal function and toxicity for medically inoperable patients with complex primary kidney tumours. The association between baseline RNS and renal function trajectories is worthy of further investigation.
引用
- Ali M, Bressel M, Chang D, et al. Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma. BJU Int. 2025. PMID: 40580074. doi:10.1111/bju.16843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。